Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma

Opinion
Video

An overview of bispecific antibodies available for the treatment of patients with relapsed/refractory multiple myeloma.

Recent Videos
4 experts are featured in this series.
3 experts in this video
3 experts in this video
3 experts in this video
3 experts in this video
Using bispecific antibodies before or after CAR T-cell therapy in multiple myeloma is an area of education for community oncologists.
3 experts in this video
3 experts in this video
2 experts are featured in this series.
9 Experts are featured in this series.
Related Content